Form 4 Tracker
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA

67 insider filings · Latest: Aug 5, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Aug 17, 2026Aug 17 8:00 PMLippman Evan
Proposed Sale
18,600$36.57$680.3K

View →

Aug 5, 2026Aug 10 10:07 AMTal Zvi ZaksDirector
Sale
17$34.87$59373,247(D)

View →

Aug 3, 2026Aug 5 8:04 PMPlacid JoverSee "Remarks"
Sale
12,827$34.88$447.4K6,774(D)

View →

Aug 3, 2026Aug 5 8:02 PMEric A HughesSee "Remarks"
Sale
25,578$34.88$892.1K134,877(D)

View →

Aug 3, 2026Aug 3 8:01 PMHughes Eric A
Proposed Sale
25,578$34.88$892.1K

View →

Aug 3, 2026Aug 3 8:00 PMJover Placid
Proposed Sale
12,827$34.88$447.4K

View →

Jun 18, 2026Jun 22 8:00 PMMatthew ShieldsEVP, Global Operations
Sale
9,989$32.19$321.5K0(D)

View →

Jun 18, 2026Jun 18 8:14 PMShields Matthew
Proposed Sale
9,989$32.19$321.5K

View →

Jun 11, 2026Jun 16 12:28 PMEliyahu Sharon KalifEVP, Chief Financial Officer
Sale
106,563$34.10$3.6M65,621(D)

View →

Jun 11, 2026Jun 11 8:00 PMKalif Eliyahu Sharon
Proposed Sale
106,563$34.10$3.6M

View →

Jun 5, 2026Jun 8 8:01 PMRichard D FrancisPresident and CEO
Sale
6,153$34.35$211.4K1,177,529(D)

View →

Jun 5, 2026Jun 5 8:00 PMFrancis Richard D
Proposed Sale
6,153$34.35$211.4K

View →

Jun 3, 2026Jun 4 8:00 PMMatthew ShieldsEVP, Global Operations
Sale
16,195$32.87$532.3K9,989(D)

View →

Jun 3, 2026Jun 3 7:59 PMShields Matthew
Proposed Sale
16,195$32.87$532.3K

View →

May 14, 2026May 18 8:02 PMEvan LippmanEVP, Business Development
Sale
41,658$35.58$1.5M44,191(D)

View →

May 14, 2026May 18 8:00 PMEliyahu Sharon KalifEVP, Chief Financial Officer
Sale
153,251$35.61$5.5M172,184(D)

View →

May 14, 2026May 14 8:02 PMLippman Evan
Proposed Sale
41,658$35.58$1.5M

View →

May 14, 2026May 14 7:59 PMKalif Eliyahu Sharon
Proposed Sale
153,251$35.61$5.5M

View →

May 6, 2026May 7 8:03 PMAmir WeissChief Accounting Officer
Sale
10,679$36.00$384.4K20,016(D)

View →

May 5, 2026May 7 8:01 PMRichard DaniellEVP, Europe Commercial
Sale
30,000$35.40$1.1M55,755(D)

View →

Page 1 of 5

Next →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Mar 4, 2026Mar 6 9:13 PMMark SabagSee "Remarks"
Option Exercise
52,11337,202(D)

View →

Mar 4, 2026Mar 6 9:11 PMEvan LippmanEVP, Business Development
Grant/Award
27,34727,347(D)

View →

Mar 4, 2026Mar 6 9:09 PMEric A HughesSee "Remarks"
Option Exercise
23,25146,503(D)

View →

Mar 4, 2026Mar 6 9:09 PMEric A HughesSee "Remarks"
Grant/Award
50,64350,643(D)

View →

Mar 4, 2026Mar 6 9:08 PMEliyahu Sharon KalifEVP, Chief Financial Officer
Option Exercise
56,76346,503(D)

View →

Mar 4, 2026Mar 6 9:08 PMEliyahu Sharon KalifEVP, Chief Financial Officer
Grant/Award
53,17553,175(D)

View →

Mar 4, 2026Mar 6 9:05 PMChristine FoxEVP, U.S. Commercial
Option Exercise
20,46140,923(D)

View →

Mar 4, 2026Mar 6 9:05 PMChristine FoxEVP, U.S. Commercial
Grant/Award
50,64350,643(D)

View →

Mar 4, 2026Mar 6 9:03 PMBrian SavageInterim Chief Legal Officer
Option Exercise
8,5107,534(D)

View →

Mar 4, 2026Mar 6 9:03 PMBrian SavageInterim Chief Legal Officer
Grant/Award
11,28011,280(D)

View →

Mar 4, 2026Mar 6 9:01 PMAmir WeissChief Accounting Officer
Grant/Award
11,28011,280(D)

View →

Mar 4, 2026Mar 6 9:01 PMAmir WeissChief Accounting Officer
Option Exercise
16,32911,300(D)

View →

Mar 3, 2026Mar 5 9:11 PMAmir WeissChief Accounting Officer
Option Exercise
5,1795,180(D)

View →

Mar 3, 2026Mar 5 9:09 PMRichard DaniellEVP, Europe Commercial
Option Exercise
203,7280(D)

View →

Mar 3, 2026Mar 5 9:08 PMMark SabagSee "Remarks"
Option Exercise
166,3780(D)

View →

Mar 3, 2026Mar 5 9:06 PMBrian SavageInterim Chief Legal Officer
Option Exercise
3,4613,461(D)

View →

Mar 3, 2026Mar 5 9:05 PMRichard D FrancisPresident and CEO
Option Exercise
958,5460(D)

View →

Mar 3, 2026Mar 5 9:03 PMEliyahu Sharon KalifEVP, Chief Financial Officer
Option Exercise
191,2780(D)

View →

Mar 3, 2026Mar 5 9:01 PMEric A HughesSee "Remarks"
Option Exercise
166,3780(D)

View →

Feb 15, 2026Feb 18 9:01 PMRichard D FrancisPresident and CEO
Option Exercise
781,7660(D)

View →